Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 13 | 2018 | 424 | 2.120 |
Why?
|
| Liver Cirrhosis | 4 | 2017 | 44 | 1.040 |
Why?
|
| Dendritic Cells | 4 | 2014 | 34 | 0.750 |
Why?
|
| Hepatitis C | 3 | 2017 | 43 | 0.710 |
Why?
|
| Lymphocyte Activation | 5 | 2014 | 82 | 0.670 |
Why?
|
| Coinfection | 2 | 2017 | 20 | 0.640 |
Why?
|
| Microbiota | 1 | 2018 | 65 | 0.530 |
Why?
|
| Aging | 2 | 2018 | 1098 | 0.520 |
Why?
|
| Hepatitis C, Chronic | 2 | 2016 | 42 | 0.510 |
Why?
|
| Viremia | 1 | 2016 | 7 | 0.510 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2016 | 1 | 0.490 |
Why?
|
| Hepatocytes | 1 | 2016 | 10 | 0.490 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 118 | 0.490 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 48 | 0.490 |
Why?
|
| T-Lymphocytes | 3 | 2010 | 95 | 0.470 |
Why?
|
| Bacterial Translocation | 1 | 2013 | 19 | 0.400 |
Why?
|
| Interferon-alpha | 2 | 2009 | 30 | 0.380 |
Why?
|
| Anti-Retroviral Agents | 2 | 2014 | 14 | 0.380 |
Why?
|
| HIV-1 | 2 | 2011 | 202 | 0.360 |
Why?
|
| Immune System | 1 | 2010 | 11 | 0.320 |
Why?
|
| Chloroquine | 1 | 2009 | 7 | 0.320 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 60 | 0.310 |
Why?
|
| Receptors, Chemokine | 2 | 2007 | 9 | 0.290 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2017 | 49 | 0.280 |
Why?
|
| Cells, Cultured | 3 | 2016 | 481 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2017 | 177 | 0.230 |
Why?
|
| Hepacivirus | 2 | 2016 | 32 | 0.230 |
Why?
|
| Interleukins | 2 | 2015 | 22 | 0.220 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2014 | 59 | 0.220 |
Why?
|
| Humans | 17 | 2018 | 23331 | 0.220 |
Why?
|
| Caspase 3 | 2 | 2016 | 17 | 0.210 |
Why?
|
| Plasma | 2 | 2014 | 13 | 0.210 |
Why?
|
| Disease Progression | 2 | 2017 | 525 | 0.210 |
Why?
|
| Adult | 11 | 2017 | 7070 | 0.200 |
Why?
|
| Flaviviridae Infections | 2 | 2013 | 2 | 0.200 |
Why?
|
| GB virus C | 2 | 2013 | 2 | 0.200 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2013 | 3 | 0.200 |
Why?
|
| Viral Load | 3 | 2014 | 69 | 0.200 |
Why?
|
| Flow Cytometry | 4 | 2012 | 104 | 0.180 |
Why?
|
| Middle Aged | 7 | 2017 | 8055 | 0.180 |
Why?
|
| Cytokines | 2 | 2013 | 213 | 0.180 |
Why?
|
| Female | 12 | 2017 | 13124 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2016 | 109 | 0.160 |
Why?
|
| HIV | 2 | 2016 | 39 | 0.150 |
Why?
|
| Antigens, CD | 2 | 2009 | 50 | 0.150 |
Why?
|
| Biological Therapy | 1 | 2018 | 2 | 0.140 |
Why?
|
| Macrophage Activation | 1 | 2017 | 8 | 0.140 |
Why?
|
| Dysbiosis | 1 | 2018 | 34 | 0.140 |
Why?
|
| Interleukin-2 | 1 | 2016 | 22 | 0.130 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 4 | 0.120 |
Why?
|
| Microscopy, Atomic Force | 1 | 2016 | 4 | 0.120 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 3 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 774 | 0.120 |
Why?
|
| Cytoskeleton | 1 | 2016 | 33 | 0.120 |
Why?
|
| Herpes Labialis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Herpes Genitalis | 1 | 2015 | 2 | 0.120 |
Why?
|
| Gene Expression | 1 | 2016 | 178 | 0.120 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2015 | 2 | 0.120 |
Why?
|
| Surface-Active Agents | 1 | 2015 | 5 | 0.120 |
Why?
|
| Nerve Regeneration | 1 | 2015 | 13 | 0.110 |
Why?
|
| Peripheral Nerves | 1 | 2015 | 15 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2013 | 88 | 0.110 |
Why?
|
| Vascular Stiffness | 1 | 2014 | 4 | 0.110 |
Why?
|
| Genotype | 1 | 2015 | 246 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 13 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 360 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 83 | 0.110 |
Why?
|
| HIV Long-Term Survivors | 2 | 2014 | 6 | 0.110 |
Why?
|
| Peptides | 1 | 2015 | 89 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1050 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2014 | 43 | 0.110 |
Why?
|
| Vagina | 1 | 2014 | 31 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 19 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 33 | 0.100 |
Why?
|
| Biomarkers | 2 | 2017 | 487 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 30 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 41 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 51 | 0.100 |
Why?
|
| Monocytes | 1 | 2013 | 49 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 6 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 262 | 0.090 |
Why?
|
| Animals | 2 | 2016 | 3287 | 0.090 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 5 | 0.080 |
Why?
|
| Receptors, CCR7 | 2 | 2007 | 7 | 0.080 |
Why?
|
| HIV Antigens | 1 | 2010 | 12 | 0.080 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 2 | 0.080 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2009 | 4 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 10 | 0.080 |
Why?
|
| Inflammation | 1 | 2011 | 235 | 0.080 |
Why?
|
| Virus Replication | 1 | 2010 | 41 | 0.080 |
Why?
|
| Imidazoles | 2 | 2007 | 62 | 0.080 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2009 | 18 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 42 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2015 | 1523 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2009 | 110 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 61 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2014 | 94 | 0.070 |
Why?
|
| Blood Cell Count | 1 | 2007 | 12 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2007 | 12 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 50 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 129 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2007 | 145 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 17 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 50 | 0.060 |
Why?
|
| Child | 1 | 2007 | 1171 | 0.050 |
Why?
|
| Adolescent | 1 | 2007 | 1916 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2013 | 1429 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2017 | 73 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 142 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 482 | 0.030 |
Why?
|
| Schwann Cells | 1 | 2015 | 2 | 0.030 |
Why?
|
| Gels | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2015 | 14 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 96 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 114 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2015 | 22 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 102 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Collagen | 1 | 2015 | 79 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 2014 | 11 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 272 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 2014 | 18 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 78 | 0.030 |
Why?
|
| Materials Testing | 1 | 2015 | 113 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2015 | 168 | 0.030 |
Why?
|
| Vaginal Douching | 1 | 2014 | 3 | 0.030 |
Why?
|
| Linear Models | 1 | 2014 | 192 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 2 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2013 | 12 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2013 | 15 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2013 | 7 | 0.030 |
Why?
|
| Rats | 1 | 2015 | 625 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 442 | 0.030 |
Why?
|
| Alleles | 1 | 2013 | 163 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 28 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 380 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 389 | 0.020 |
Why?
|
| United States | 1 | 2017 | 1829 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 1998 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 2 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2011 | 34 | 0.020 |
Why?
|
| Poly I-C | 1 | 2006 | 5 | 0.020 |
Why?
|
| Ligands | 1 | 2006 | 39 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2006 | 74 | 0.010 |
Why?
|
| Male | 1 | 2012 | 12629 | 0.010 |
Why?
|